PharmaVoice

JULY 18, 2022

The pandemic has forced the pharmaceutical industry to look at digital in a new way - and it’s driving better health outcomes

263

263

Pharmacy Times

JULY 18, 2022

Pharmacists can leverage patient medical history for formulating effective drugs, and patients can also benefit from single dosage, greater efficacy, and affordability of compounded medications.

Compounding 162

Compounding Compounding Pharmacies Dosage 162

pharmaphorum

JULY 18, 2022

Pierre A. Morgon, PharmD, LL.M, MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Convidencia’s injectable version was granted World Health Organization (WHO) Emergency Use Listing (EUL), and its inhalant counterpart, currently in phase three clinical tr

Vaccines 138

Vaccines Health and Personal Care Stores Immunization Packaging 138

Pharmacy Times

JULY 18, 2022

Use of these drugs as medications, though, promising, may be restricted for various reasons to a select few.

159

159

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

PharmaVoice

JULY 18, 2022

The latest executive personnel changes from around the industry.

130

130

Pharmacy Times

JULY 18, 2022

Patients with diabetes on Medicare Advantage were also less likely to be prescribed newer, more expensive medicine than patients on Medicare Fee-For-Service plans, indicating potential disparities in care.

139

139

Pharmacy Times

JULY 18, 2022

Health system specialty pharmacies help remove barriers to care, optimize therapy, and improve outcomes.

Specialty Pharmacies 123

Specialty Pharmacies 123

pharmaphorum

JULY 18, 2022

As you know, clinical trials can be complex. Industry standards are now required for clinical trial submission. This means even more associated costs, resources, time, and effort. The Formedix clinical metadata repository ( MDR ) can help! So what can it do for you? In a nutshell, it can help you: How is this possible? Take studies and standards for example.

Communication 98

Communication 98

Pharmacy Times

JULY 18, 2022

A study demonstrated the role of the serotonin 1B receptor in appetite and showed that triptan, a commonly prescribed migraine medicine, may be repurposed for appetite suppression and obesity.

123

123

European Pharmaceutical Review

JULY 18, 2022

About haemophilia. Haemophilia is a rare disease affecting an estimated 1.125 million people worldwide that impairs the body’s clotting ability. Haemophilia A and B are more common in males, with approximately 88 percent of people diagnosed with haemophilia worldwide being male. Haemophilia A is an inherited disorder in which people lack the clotting protein factor VIII.

Immunization 98

Immunization Hospitals 98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

JULY 18, 2022

Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

123

123

European Pharmaceutical Review

JULY 18, 2022

Grünenthal has agreed to acquire testosterone treatment Nebido TM and its associated brands from Bayer AG, for up to €500 million. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries. Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States.

98

98

Pharmacy Times

JULY 18, 2022

It's really important that we capitalize on this time and the impact that pharmacists had to make some of this reform permanent.

122

122

European Pharmaceutical Review

JULY 18, 2022

Treatment with both higher and lower doses of Dupixent ® (dupilumab) resulted in histological disease remission at 16 weeks in children aged one to 11 years with eosinophilic oesophagitis (EoE) – achieving the Phase III trial’s primary endpoint. EoE is a chronic inflammatory disease that damages the oesophagus and prevents it from functioning properly.

94

94

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

JULY 18, 2022

If we are culturally competent, then we know the impacts of social determinants of health can have and how racism and transphobia homophobia can contribute to the social determinants of health.

119

119

Pharmaceutical Technology

JULY 18, 2022

Quoin Pharmaceuticals and Endo International subsidiary Endo Ventures have signed a licence and distribution agreement and a supply agreement to develop, register, supply, market and distribute the former’s QRX003 exclusively in Canada. A lead product of Quoin, QRX003 is a topical lotion intended to treat Netherton Syndrome. As per the terms of the license and distribution deal, Endo holds the exclusive right, which was also sublicensed to the affiliate of the company, Paladin Labs, to market th

64

64

Pharmacy Times

JULY 18, 2022

Building a team to support best practices, medication safety, and staff education will reduce risks.

118

118

Pharmaceutical Technology

JULY 18, 2022

GlaxoSmithKline (GSK) has signed an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to aid in protecting adults and children in the country. Spanning to March 2026, the four-year agreement comprises the delivery of nearly 80 million doses of adjuvanted pandemic influenza vaccine, Arepanrix, and at least four million doses of seasonal influenza vaccine, Flulaval Tetra, each year.

Vaccines 64

Vaccines Immunization 64

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JULY 18, 2022

Ryan Burke, PharmD, director of professional affairs at Pharmacy Technician Certification Board, discusses how the changing role of pharmacy technicians has also helped the role of the pharmacist.

117

117

Pharmaceutical Technology

JULY 18, 2022

The European Commission (EC) has granted conditional marketing authorization (CMA) for Calliditas Therapeutics’ Kinpeygo to treat primary immunoglobulin A (IgA) nephropathy (IgAN) in adults. The treatment is indicated for IgAN patients at risk of quick disease progression risk with a urine protein-to-creatinine ratio (UPCR) ?1.5g/gram. . An orphan medicinal product, Kinpeygo is the first and only therapy to receive approval for IgAN.

64

64

Pharmacy Times

JULY 18, 2022

Persistence by pharmacists and showing patients respect can help overcome misinformation.

Vaccines 86

Vaccines 86

Outsourcing Pharma

JULY 18, 2022

A pediatric clinical trial expert from the CRO discusses the unique challenges involved in designing a study when the patients involved are little ones.

59

59

Pharmacy Times

JULY 18, 2022

Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.

73

73

Pharmaceutical Technology

JULY 18, 2022

Bronchiectasis is defined by the permanent and abnormal damage to the bronchi, causing dilation and scarring, and usually occurs in the context of chronic airway infection and inflammation, often with thick and difficult-to-clear mucus. Bronchiectasis occurs across age groups but is most prevalent in adults and more common in females. Symptoms vary from excessive coughing, chest discomfort, and even weight loss, exacerbating other symptoms such as breathlessness.

Labelling 59

Labelling 59

Pharmacy Times

JULY 18, 2022

Red Cross Canker Sore Medication is used for temporary relief of pain and minor irritation of the mouth and gums due to sores, minor dental procedures, braces, and dentures.

65

65

pharmaphorum

JULY 18, 2022

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight competitors Roche and AstraZeneca/Daiichi Sankyo. The Dutch biotech submitted the ADC to the FDA last week and said this morning the EMA had formally started its review of the drug for HER2-positive, locally advanced or metastatic breast cancer that can’t be treated with surgery.

FDA 59

FDA 59

Pharmacy Times

JULY 18, 2022

Apomorphine (Kynmobi) is indicated for the acute, intermittent treatment of off episodes in patients with Parkinson disease.

65

65

Board Vitals - Pharmacist

JULY 18, 2022

The United States Medical Licensure Exam (USMLE) Step 1, commonly called “the Boards,” is a standardized test that assesses a medical student’s ability to apply basic science fundamentals to the practice of medicine. The entire exam has three steps, but this article applies only to Step 1. Students take Step 1 following their second year of medical school.

Medical Schools 52

Medical Schools 52

Pharmacy Times

JULY 18, 2022

Maker of Sensodyne, Advil, and TUMS becomes one of the world’s leading independent consumer health companies.

65

65

The Guardian - Pharmaceutical Industry

JULY 18, 2022

Consumer health company ends first day on London Stock Exchange with £28.5bn market valuation Opinion: Haleon may not be the jewel in GSK’s medicine cabinet GSK’s consumer spin-off Haleon, home to brands from Sensodyne toothpaste to Panadol painkillers, has begun trading on the London Stock Exchange in the biggest European listing in a decade. Haleon shares started trading on Monday morning at 330p, with a market value of about £31bn, but at the end of day one it was £28.5bn.

52

52

Pharmacy Times

JULY 18, 2022

Data from Roche’s phase 3 HAVEN 6 study show clinically meaningful bleed control, with no new safety signals observed.

65

65

Oswald's

JULY 18, 2022

It can be tough to find solutions for strains and stress that don’t include some sort of medication. Stress, both mental & physical, can be a huge detriment to your daily life, one that you may be using OTC medications to relieve.* We have been looking for all-natural solutions to add comfort to everyday problems… The post All-Natural Solutions for Comfort appeared first on Oswald's Pharmacy.

52

52

pharmaphorum

JULY 18, 2022

UK startup Oto has raised £2.8 million ($3.3 million) in seed financing for a mobile app that aims to help people with tinnitus manage the ringing, buzzing or other noises in their ears that can wreak havoc with their quality of life. The app doesn’t promise to treat tinnitus – in fact there are no approved therapies for the condition, which affects one in seven people worldwide.

People Management 52

People Management 52